Thrombosed hemodialysis grafts: Lyse and wait with tissue plasminogen activator or urokinase compared to mechanical thrombolysis with the Arrow-Trerotola Percutaneous Thrombolytic Device

Journal of Vascular and Interventional Radiology

Volumn 12, Issue 10, 2001, Pages 1157-1165

  Vogel, P M ^a   Marshall, V ^a   Bansal, M W ^a  

^a NONE   (United States)

Author keywords

Dialysis, shunts; Grafts; Thrombolysis; Thrombosis

Indexed keywords

ALTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ADULT; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BLOOD VESSEL GRAFT; CLINICAL TRIAL; COMPRESSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; FEMALE; GRAFT PATENCY; HEMODIALYSIS; HEMOSTASIS; HOSPITALIZATION; HUMAN; MALE; PERCUTANEOUS THROMBECTOMY DEVICE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TECHNIQUE; THROMBOSIS; TREATMENT OUTCOME;

EID: 0034774949     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1051-0443(07)61672-8     Document Type: Article

References (38)

1. Improved treatment of thrombosed hemodialysis access sites, with thrombolysis and angioplasty
2. Thrombosed dialysis grafts: Comparison of treatment with transluminal angioplasty and surgical revision
3. Thrombolysis versus surgery for the treatment of thrombosed dialysis access grafts
4. Pulse-spray pharmacomechanical thrombolysis of thrombosed hemodialysis access grafts: Long-term experience and comparison of original and current techniques
5. Manual thromboaspiration and dilation of thrombosed dialysis access: Mid-term results of a simple concept
6. Percutaneous balloon assisted aspiration thrombectomy of clotted hemodialysis access grafts
7. Thrombosed hemodialysis grafts: Percutaneous mechanical balloon declotting versus thrombolysis
8. Mechanical declotting of thrombosed dialysis grafts: Experience in 86 cases
9. Mechanical thrombolysis for the treatment of thrombosed hemodialysis access grafts
10. Hemodialysis graft declotting: Description of the lyse and wait technique
11. Multicenter prospective randomized comparison of "lyse and wait" versus pulse-spray pharmacomechanical thrombolysis for treating thrombosed hemodialysis access grafts
12. Retrospective comparison of the Amplatz Thrombectomy Device with modified pulse-spray pharmacomechanical thrombolysis in the treatment of thrombosed hemodialysis access grafts
13. Hydrodynamic thrombectomy of hemodialysis fistulas: First clinical results
14. Treatment of thrombosed hemodialysis access grafts: Arrow-Trerotola percutaneous thrombolytic device versus pulse-spray thrombolysis
15. Modified use of the Arrow-Trerotola Percutaneous Thrombolytic Device for the treatment of thrombosed hemodialysis access grafts
16. Treatment of thrombosed dialysis access grafts: Randomized trial of surgical thrombectomy versus mechanical thrombectomy with the Amplatz device
17. Synthetic dialysis shunts: Thrombolysis with the Cragg thrombolytic brush catheter
18. Reporting standards for percutaneous interventions in dialysis access
19. Quality improvement guidelines for percutaneous management of the thrombosed or dysfunctional dialysis access
20. Relationship between dialysis graft pressure and stenosis
21. Hemodynamics of failing dialysis grafts
22. Lyse and wait declotting with low-dose rt-PA: Disappointing early experience
23. Tissue plasminogen activator in hemodialysis grafts
24. Initial experience with reteplase using the "lyse and wait" technique in thrombosed dialysis grafts
25. Mechanical versus pharmacomechanical thrombolysis for the treatment of thrombosed dialysis access grafts
26. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin
27. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro
28. Transport processes in fibrinolysis and fibrinolytic therapy
29. Efficacy of adjunctive intrathrombotic heparin with pulse-spray thrombolysis in rabbit inferior cava thrombosis
30. Thrombolysis of clotted hemodialysis grafts with tissue-type plasminogen activator
31. Pulmonary emboli from pulse-spray and mechanical thrombolysis: Evaluation with an animal dialysis-graft model
32. Phrmacomechanical thrombolysis with urokinase for treatment of thromboses hemodialysis access grafts
33. The use of tissue plasminogen activator to declot arteriovenous access in hemodialysis patients
34. Recombinant tissue plasminogen activator (rt-PA) as first-line therapy for declotting of haemodialysis access
35. A comparison of the thrombolytic and hemorrhagic effects of tissue-type plasminogen activator and streptokinase in rabbits
36. Sustained thrombolysis with DNA-recombinant tissue type plasminogen activator in rabbits
37. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans
38. Use of a purse string suture to close a percutaneous access site after hemodialysis graft interventions